<DOC>
	<DOCNO>NCT01082120</DOCNO>
	<brief_summary>The purpose study determine whether administration AZD1656 affect pharmacokinetics Pioglitazone vice versa patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Investigate Effect AZD1656 Pharmacokinetics Pioglitazone Vice Versa Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients confirm Type 2 Diabetes Mellitus least 1 year treat metformin alone metformin one oral antidiabetic drug Body mass index ≥19 ≤42 kg/m2 . Impaired renal function Clinically significant illness clinically relevant trauma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Pioglitazone</keyword>
</DOC>